Ring Containing Patents (Class 514/559)
-
Publication number: 20130158119Abstract: Pharmaceutical semi-solid composition of Isotretinoin An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e.Type: ApplicationFiled: June 18, 2012Publication date: June 20, 2013Inventors: Francis Vanderbist, Cécile Servais, Philippe Baudier
-
Publication number: 20130150445Abstract: Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer.Type: ApplicationFiled: August 8, 2012Publication date: June 13, 2013Inventors: Robert G. L. Shorr, Robert J. Rodriguez, Rajinder Bhasin
-
Publication number: 20130143966Abstract: The use of sterculic acid, and the pharmaceutically acceptable salt forms thereof, described for the treatment of inflammation, in particular, 7-ketocholesterol induced inflammation, 7-keto-cholesterol toxicity, and unregulated angiogenesis.Type: ApplicationFiled: June 24, 2011Publication date: June 6, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Ignacio R. Rodriguez, Jiahn-Dar Huang, Juan A. Amaral, Jung Wha Lee, William Samuel, Ignacio Marcos Larrayoz
-
Patent number: 8440718Abstract: This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.Type: GrantFiled: January 22, 2004Date of Patent: May 14, 2013Assignee: The Brigham and Women's Hospital, Inc.Inventors: James L. Madara, Charles N. Serhan, Sean P. Colgan
-
Patent number: 8420698Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.Type: GrantFiled: December 23, 2010Date of Patent: April 16, 2013Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L Wiech
-
Publication number: 20130089575Abstract: The present invention is directed to methods and compositions for topical administration of acitretin. More specifically, the present invention is related to methods and compositions for the treatment or prevention or reduction of symptoms or signs of dermatological conditions using acitretin in a topical administration. More specifically, the present invention is related to methods and compositions containing acitretin which are effective for the treatment or prevention or reduction of symptoms or signs of keratoses, in particular actinic keratosis.Type: ApplicationFiled: October 1, 2012Publication date: April 11, 2013Applicant: DOUGLAS PHARMACEUTICALS LTD.Inventors: Peter Surman, Fergus Cameron Binnie, Marten Geert Vos
-
Publication number: 20130065850Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.Type: ApplicationFiled: April 3, 2012Publication date: March 14, 2013Applicant: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Josh MUNGER, Bryson BENNETT, Thomas SHENK, Joshua RABINOWITZ
-
Publication number: 20130065870Abstract: The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.Type: ApplicationFiled: October 31, 2012Publication date: March 14, 2013Applicant: Nuvo Research Inc.Inventor: Nuvo Research Inc.
-
Publication number: 20130059787Abstract: RA treatment can improve cognition; promote neurogenesis; and regulate alternative splicing of genes, particularly by mediating mechanisms of 5? splice site selection and generation of PKC? alternatively spliced variants. Expression of PKC?VIII is an indicator of the levels of on-going apoptosis in neurons. In the aging brain, switching the isoform expression to PKC?VIII by RA could shield the cells from neuronal death. The inventors discovered that human PKC?VIII expression is increased in neuronal cancer and decreased in Alzheimer's disease. The data shows that PKC?VIII promotes neuronal survival and increases neurogenesis via Bcl2 and Bcl-xL. In addition, the trans-factor SC35 was found to be crucial in mediating the effects of RA on alternative splicing of PKC?VIII mRNA in neurons. The data described herein indicate that PKC?VIII can be used as a biomarker for neurological diseases such as cancers and Alzheimer's disease and as a tool for monitoring and evaluating treatment.Type: ApplicationFiled: August 17, 2012Publication date: March 7, 2013Applicants: UNITED STATES DEPARTMENT OF VETERAN AFFAIRS, UNIVERSITY OF SOUTH FLORIDAInventors: Niketa A. Patel, Denise R. Cooper
-
Publication number: 20130041016Abstract: Compositions and methods of using compositions that induce UBE1L or a ubiquitin-like protein ISG15, or inhibit a deconjugase UBP43 to degrade oncogenic proteins and enhance apoptosis of cancer (neoplastic) or pre-cancerous (pre-neoplastic) cells are provided. Methods for the prevention or treatment of cancer via administration of these compositions are also provided.Type: ApplicationFiled: September 17, 2012Publication date: February 14, 2013Applicant: Trustees of Dartmouth CollegeInventors: Ethan Dmitrovsky, Bret C. Hassel, Sutisak Kitareewan, Ian Pitha-Rowe
-
Patent number: 8354448Abstract: The present invention provides the use of (?)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.Type: GrantFiled: July 16, 2009Date of Patent: January 15, 2013Assignee: Metabolex, Inc.Inventors: Kenneth L. Luskey, Jian Luo
-
Publication number: 20130012582Abstract: A formulation for topical use having a filmogenic (peel-off) action for professional and home use, containing high concentrations of Retinoic acid, the method of production and use thereof in the treatment of acne, wrinkles, hyperpigmentations, psoriasis and all imperfections linked to keratinization disorders. The composition also comprises octyldodecyl octyldodecanoate, and polyvinyl alcohol. The composition is in the form of a face mask (pack).Type: ApplicationFiled: September 9, 2011Publication date: January 10, 2013Applicant: LABORATORI FARMACEUTICI KRYMI S.P.A.Inventors: Rocco Crimi, Raniero Cozzi
-
Publication number: 20120315324Abstract: An exosomal composition is provided that comprises a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a Stat3 inhibitor. Pharmaceutical compositions comprising the exosomal compositions are also provided. Methods for treating an inflammatory disease or a cancer are further provided and include administering an effective amount of an exosomal composition to a subject in need thereof to thereby treat the inflammatory disorder or the cancer.Type: ApplicationFiled: February 4, 2011Publication date: December 13, 2012Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventor: Huang-Ge Zhang
-
Publication number: 20120316240Abstract: Disclosed herein are methods that generally to the fields of pharmaceutical chemistry, biochemistry, molecular biology and medicine. More particularly, aspects of the invention concern methods to identify a predisposition for fibrosis in a biological sample, methods of identifying agents that modulate the onset of fibrosis, methods of making a formulation that inhibits the onset or progression of fibrosis, and methods of monitoring the progression of fibrosis or the efficacy of a fibrosis treatment.Type: ApplicationFiled: December 13, 2011Publication date: December 13, 2012Applicant: NITTO DENKO CORPORATIONInventors: Shaochun Song, Yun Liu, Nan Jiang, Lei Yu
-
Publication number: 20120316241Abstract: The present invention relates an agent for treating cartilage-related disease comprising as an active ingredient a substance having an EP2 and/or EP3 agonist activity. A substance having an agonist activity to EP2 and/or EP3 has effects of stimulating chondrogenesis, stimulating chondrocyte growth, stimulating chondrocyte differentiation, inhibiting cartilage calcification and inhibiting cartilage degradation, or effects of stimulating integrin mRNA expression, stimulating fibronectin mRNA expression, stimulating D1 mRNA expression and inhibiting osteopontin mRNA expression, and, therefore, is useful as an agent for treating cartilage-related disease.Type: ApplicationFiled: July 2, 2012Publication date: December 13, 2012Applicant: ONO PHARMACEUTICAL CO., LTD.Inventor: Junya TOGUCHIDA
-
Publication number: 20120316242Abstract: A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) ?/? of the cells.Type: ApplicationFiled: July 3, 2012Publication date: December 13, 2012Applicant: CASE WESTERN RESERVE UNIVERSITYInventor: Noa Noy
-
Patent number: 8329749Abstract: The present invention provides the use of (?)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.Type: GrantFiled: July 16, 2009Date of Patent: December 11, 2012Assignee: Metabolex, Inc.Inventors: Kenneth L. Luskey, Jian Luo
-
Patent number: 8329747Abstract: There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer.Type: GrantFiled: August 4, 2009Date of Patent: December 11, 2012Assignee: Centro de Recherche sur les Biotechnologies MarinesInventor: Samuel Fortin
-
Publication number: 20120288568Abstract: Compounds that reduce serum retinol, serum RBP, and/or serum retinol-RBP levels may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.Type: ApplicationFiled: May 17, 2012Publication date: November 15, 2012Applicant: Revision Therapeutics, Inc.Inventors: Kenneth Widder, Jay Lichter, Nathan L. Mata
-
Patent number: 8304575Abstract: The present invention relates to a process for producing an ether carboxylate which includes the steps of (1) reacting an aliphatic monohydric alcohol with an alkylene oxide in the presence of an alkali catalyst; (2) neutralizing a reaction solution obtained in the step (1) with an acid such as hydroxycarboxylic acids to obtain an ether alcohol; and (3-1) reacting the obtained ether alcohol with a monohalogenofatty acid or a salt thereof and an alkali metal hydroxide, or (3-2) subjecting the obtained ether alcohol to catalytic oxidation reaction in the presence of a catalyst. The obtained ether carboxylate has a less odor and a high quality and is therefore suitably used in the applications such as cosmetics and toiletries.Type: GrantFiled: April 3, 2008Date of Patent: November 6, 2012Assignee: Kao CorporationInventors: Akira Matsunaga, Kaoru Ohmae
-
Patent number: 8299122Abstract: A method for stabilizing retinoic acid is provided. The method includes a step of mixing retinoic acid with a hydrophobic polymer/hydrophilic polymer adduct in the presence of an oxygen containing atmosphere to form a retinoic acid containing composition. The hydrophobic polymer/hydrophilic polymer adduct comprises a poly(vinylpyrrolidone/alkylene) polymer and a polymer comprising repeating carboxylic acid groups, hydroxyl groups, or a mixture of carboxylic acid groups and hydroxyl groups. A retinoic acid containing composition and a method of using a retinoic acid containing composition are provided.Type: GrantFiled: April 14, 2009Date of Patent: October 30, 2012Assignee: Skinvisible Pharmaceuticals, Inc.Inventor: James A. Roszell
-
Publication number: 20120269802Abstract: The present invention provides a method treating a myeloma patient by administering one or more of thalidomide, a Total Therapy 2 regimen, an interleukin-6 signaling suppressor, an interleukin-6R signaling suppressor, an IGF1 signaling suppressor, an IGF1 R signaling suppressor, shRNA or other modulators of gene expression. Also, provided are methods for predicting outcome of a treatment for an individual having a cancer, e.g., myeloma, by performing one or more of karyotyping or expression profiling of chromosomes 1 and 13 or expression level measurement of IL-6R.Type: ApplicationFiled: October 13, 2010Publication date: October 25, 2012Inventors: John D. Shaughnessy, JR., Bart Barlogie
-
Publication number: 20120270945Abstract: The present invention relates to a method for modulating cytokine activity, immunomodulation or treating esophagitis comprising an administration of a fatty acid derivative to a mammalian subject. The present invention also relates to a composition for modulating cytokine activity, immunomodulation or treating esophagitis comprising a fatty acid derivative.Type: ApplicationFiled: April 18, 2012Publication date: October 25, 2012Applicant: SUCAMPO AGInventor: Ryuji UENO
-
Publication number: 20120269874Abstract: The invention relates to a composition for topical application comprising as an active ingredient a peroxide and a retinoid wherein one of said peroxide and retinoid is in the form of first microparticles comprising a solid particulate matter of the active ingredient coated by a metal oxide layer and the other of said peroxide and retinoid is present in an uncoated free form or in a coated form of the active ingredient. The invention further relates to method for treating a surface condition in a subject using said composition, a method for preparing a composition exhibiting improved stability, and a kit comprising: (a) a first composition comprising a peroxide as a first active ingredient; and (b) a second composition comprising a retinoid as a second active ingredient; at least one of said first and said second active ingredient being coated by a metal oxide layer.Type: ApplicationFiled: June 13, 2012Publication date: October 25, 2012Applicant: SOL-GEL TECHNOLOGIES LTD.Inventors: Ofer TOLEDANO, Hanan SERTCHOOK, Natalia LOBODA, Haim BAR-SIMANTOV, Leora SHAPIRO, Raed ABU-REZIQ
-
Publication number: 20120264713Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.Type: ApplicationFiled: January 15, 2011Publication date: October 18, 2012Inventors: Charles N. Serhan, Bruce D. Levy
-
Patent number: 8287893Abstract: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations.Type: GrantFiled: May 19, 2008Date of Patent: October 16, 2012Assignee: Sciessent LLCInventor: Joseph J. Crudden
-
Patent number: 8288438Abstract: Compounds, compositions, and methods of avoiding edema while treating or preventing PPAR?-mediated diseases, including cancer, using derivatives and prodrugs are provided.Type: GrantFiled: March 21, 2006Date of Patent: October 16, 2012Assignees: Metabolex, Inc., Dia Tex, Inc.Inventors: Martin E. Sanders, David B. Karpf
-
Patent number: 8282949Abstract: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising metal-acid solutions.Type: GrantFiled: May 19, 2008Date of Patent: October 9, 2012Assignee: Sciessent LLCInventor: Joseph J. Crudden
-
Patent number: 8278332Abstract: The photostabilizing electronic excited state energy—particularly singlet state energy from retinoid compounds—has been found to be readily transferred to (accepted by) ?-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase the photostability of retinoid compounds in a composition by at least 3-fold.Type: GrantFiled: October 27, 2011Date of Patent: October 2, 2012Assignee: Hallstar Innovations Corp.Inventors: Craig A. Bonda, Anna Pavlovic, Jean Zhang
-
Patent number: 8273791Abstract: Compositions, kits and regimens for treatment of damaged skin, especially décolletage, include application of a retinoid, hydroquinone or hydroquinone derivatives, and a composition containing a multi-metal complex.Type: GrantFiled: December 10, 2008Date of Patent: September 25, 2012Assignee: JR Chem, LLCInventors: José E. Ramirez, Joseph R. Faryniarz
-
Patent number: 8268294Abstract: The photostabilizing electronic excited state energy—particularly singlet state energy from retinoid compounds—has been found to be readily transferred to (accepted by) ?-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase the photostability of retinoid compounds in a composition by at least 3-fold and as much as 10-fold or greater. The ability of the alkoxycrylene compounds to stabilize the retinoid compound is concentration dependent, with the amount of retinoid photostabilization increasing with the concentration of the alkoxycrylene compound.Type: GrantFiled: February 22, 2011Date of Patent: September 18, 2012Assignee: Hallstar Innovations Corp.Inventors: Craig A. Bonda, Anna Pavlovic, Jean Zhang
-
Publication number: 20120232140Abstract: The present invention relates to a pharmaceutical combination comprising a prostaglandin compound and a NSAID. The present invention particularly relates to an ophthalmic composition comprising travoprost and bromfenac for the treatment of glaucoma and ocular hypertension.Type: ApplicationFiled: November 1, 2010Publication date: September 13, 2012Applicant: MICRO LABS LIMITEDInventors: Rajesh Kshirsagar, Chandrashekar Kadam, Pravin Kamble, SM Mudda
-
Patent number: 8263050Abstract: The photostabilizing electronic excited state energy—particularly singlet state energy from a UV-absorbing molecule has been found to be readily transferred to (accepted by) ?-cyanodiphenylacrylate compounds of formulas (I) and (V) having an alkoxy radical preferably in the four (para) position (hereinafter methoxycrylenes) on one or both of the phenyl rings: wherein at least one of R1 and R2 is a straight or branched chain C1-C12 alkoxy radical, preferably C1-C8, more preferably C1-C4, and most preferably methoxy, and any non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C24 alkyl radical, preferably C12-C24, more preferably C20; wherein A and B are the same or different and are selected from the group consisting of oxygen, amino and sulfur; R1 and R3 are the same or different and are selected from the group consisting of C1-C30 alkyl, C2-C30 alkylene, C2-C30 alkyne, C3-C8 cycloalkyl, C1-C30 substituted alkylene, C2-C30 substituted alkyne, aryl, substituted aryl, hetType: GrantFiled: April 29, 2009Date of Patent: September 11, 2012Assignee: Hallstar Innovations Corp.Inventors: Craig A. Bonda, Anna Pavlovic
-
Patent number: 8263051Abstract: The photostabilizing electronic excited state energy—particularly singlet state energy from resveratrol compounds—has been found to be readily transferred to (accepted by) ?-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase the photostability of resveratrol compounds in a composition by at least 3-fold and as much as 10-fold or greater. The ability of the alkoxycrylene compounds to stabilize the resveratrol compound is concentration dependent, with the amount of resveratrol photostabilization increasing with the concentration of the alkoxycrylene compound.Type: GrantFiled: April 5, 2011Date of Patent: September 11, 2012Assignee: Hallstar Innovations Corp.Inventors: Craig A. Bonda, Anna Pavlovic, Jean Zhang
-
Publication number: 20120225938Abstract: The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound.Type: ApplicationFiled: May 14, 2012Publication date: September 6, 2012Applicant: SUCAMPO AGInventor: Ryuji UENO
-
Publication number: 20120225102Abstract: A perfluorocarbon gel composition is disclosed with numerous uses including topical medical and cosmetic uses.Type: ApplicationFiled: April 16, 2012Publication date: September 6, 2012Inventors: Gerald Klein, Richard Kiral, Chris J. Stern
-
Patent number: 8236755Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one opioid bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: GrantFiled: May 14, 2007Date of Patent: August 7, 2012Assignee: Camurus ABInventors: Krister Thuresson, Fredrik Tiberg, Markus Johansson, Ian Harwigsson, Fredrik Joabsson, Markus Johnsson
-
Patent number: 8236292Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: GrantFiled: June 6, 2005Date of Patent: August 7, 2012Assignee: Camurus ABInventors: Krister Thuresson, Fredrik Tiberg, Markus Johansson, Ian Harwigsson, Fredrik Joabsson, Markus Johnsson
-
Publication number: 20120195861Abstract: Described herein are the use of peripheral blood derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.Type: ApplicationFiled: January 14, 2011Publication date: August 2, 2012Applicant: The General Hospital CorporationInventors: Jonathan L. Tilly, Joshua Johnson
-
Publication number: 20120189678Abstract: A liposome comprising a phospholipid, a hydrophobic active comprising a carboxylate group, and a component selected from a group consisting of: a hydrophilic adjuvant comprising a positively charged group, a complex of said hydrophobic active with said hydrophilic adjuvant, and combinations thereof. An aqueous liposome dispersion comprising the liposome, and a personal care composition comprising the liposome. A process of preparing the liposome, comprising the steps of: forming a premix by dissolving a phospholipid, a hydrophobic active comprising a carboxylate group in an organic solvent; evaporating off said organic solvent from the premix to form a phospholipid film; and hydrating said lipid film with a hydration medium comprising a hydrophilic adjuvant comprising a positively charged group and homogenize the medium to form an aqueous liposome dispersion.Type: ApplicationFiled: January 25, 2012Publication date: July 26, 2012Inventors: Chengwu LI, Naohisa Yoshimi, Xincheng Hu, Shuang Li, Yunhua Gao
-
Patent number: 8226933Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to about 50% of a combination of retinoid boosters.Type: GrantFiled: April 29, 2011Date of Patent: July 24, 2012Assignee: Unilever Home & Personal Care, USA division of Conopco, Inc.Inventors: Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
-
Publication number: 20120178812Abstract: Pharmaceutical formulations containing lipoic acid derivatives are made.Type: ApplicationFiled: October 5, 2011Publication date: July 12, 2012Inventors: Robert G.L. Shorr, Robert J. Rodriguez, Rajinder Bhasin
-
Publication number: 20120172326Abstract: The present invention refers to a moisturizing mixture for sensitive skins, atopic dermatitis and/or Ichthyosis vulgaris containing a synergistic combination among its constituents, and cosmetic and/ pharmaceutical compositions containing said moisturizing mixture. The invention also refers to a moisturizing mixture comprising a synergistic combination between at least one cutaneous-barrier repairing agent; NMF-precursor amino acids; and at least one filagrin-synthesis stimulating agent. Cosmetic and/or pharmaceutical compositions comprising said moisturizing mixture and a physiologically acceptable carrier are also described in the present invention.Type: ApplicationFiled: November 27, 2009Publication date: July 5, 2012Applicant: Natura Cosmeticos S.A.Inventors: Patricia Da Luz Moreira, Adriano Tadeu Siqueira Jorge, Juliana Palmeira Portugal Marques, Jean Luc Gesztesi, Philip Leite Ribeiro, Sara Rocha
-
Publication number: 20120149768Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.Type: ApplicationFiled: February 21, 2012Publication date: June 14, 2012Inventors: Thomas J. Nelson, Daniel L. Alkon
-
Publication number: 20120148695Abstract: The invention refers to pharmaceutical compositions based on oil extracted from the seeds of Carapa Guianensis Aublet and/or of chemical compounds isolated from this oil and responsible for its biological activity, the tetranortriterpenoids, presenting the following pharmacological activities: anti-allergenic, anti-inflammatory, analgesic and immune modulating with reduced side effects and low cost. Such pharmaceutical compositions of this invention are aimed at the treatment, or prevention, or inhibition of allergenic an inflammatory conditions in human beings, through oral or topic use. In each one of these cases, the composition can be in the liquid or solid form. Compounds for topic use of this invention are atoxic, or with low toxicity, and, specially, provided in the semi-solid form (cream).Type: ApplicationFiled: July 21, 2005Publication date: June 14, 2012Inventors: Maria das Gracas Henriques, Carmem Penido Monteiro, Antonio Carlos Siani, Jislaine de Fatima Guilhermino, Monica Freiman de Souza Ramos, Andre Luiz Franco Sampaio, Elaine Cruz Rosas, Lucilene Azevedo de Lima, Renato Jabour Pennaforte
-
Publication number: 20120149771Abstract: The use of lipoxin analogs for the treatment or prevention of asthma and asthma related diseases is described. In particular, acetylenic lipoxin analogs are effective for the treatment and prevention of eosinophil recruitment involved with the inflammation processes associated with asthma, asthma like conditions, and lung injuries associated from airway inflammation or infection as brought about by leukocyte-mediated injury from within.Type: ApplicationFiled: February 21, 2012Publication date: June 14, 2012Applicant: The Brigham and Women's HospitalInventors: Charles N. Serhan, Bruce D. Levy
-
Patent number: 8198249Abstract: A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient.Type: GrantFiled: May 4, 2010Date of Patent: June 12, 2012Assignee: Board of Trustees of Michigan State UniversityInventors: Muraleedharan G. Nair, Bolleddula Jayaprakasam, Lawrence K. Olson, Robert E. Schutzki
-
Patent number: 8198324Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.Type: GrantFiled: August 6, 2009Date of Patent: June 12, 2012Assignee: Centre de Recherche sur les Biotechnologies MarinesInventor: Samuel Fortin
-
Publication number: 20120129930Abstract: The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: ApplicationFiled: November 15, 2011Publication date: May 24, 2012Applicant: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri DASSEUX, Daniela Carmen ONICIU
-
Patent number: 8183272Abstract: Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof:Type: GrantFiled: June 23, 2011Date of Patent: May 22, 2012Assignee: Daiichi Sankyo Company, LimitedInventors: Akira Nakao, Kentoku Gotanda, Kazumasa Aoki, Shimpei Hirano, Yoshiharu Hiruma, Takeshi Shiiki